Amyloidosis is a rare and serious protein deposition disease and is caused by an abnormal protein known as amyloid that builds up in the tissues or organs. As the amount of amyloid protein deposits increases in a tissue or organ, they interfere with the tissue or organ’s healthy function. Eventually, the amyloid protein deposits can cause symptoms and organ failure and sometimes can be fatal. There are different types of amyloidosis such as, Light chain (AL) amyloidosis, Autoimmune (AA) amyloidosis, Hereditary or familial amyloidosis. The amyloid proteins that build up in the tissues in this condition are known as light chains. The drug candidates of Amyloidosis pipeline include, but are not limited to, NEOD001, Patisiran and Small interfering RNA. Some of the companies having a pipeline of amyloidosis drug candidates include Alnylam Pharmaceuticals, Inc., Amgen Inc., and Arcturus Therapeutics, Inc.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.